Dr. Reddy's Laboratories Limited has announced a significant leadership change with the elevation of Mr. M S Madhu Sundar to the position of Global Head of Quality and PV. The pharmaceutical company's Board of Directors approved this appointment on March 10, 2026, based on the recommendation of the Nomination, Governance and Compensation Committee.

Leadership Elevation Details

The appointment becomes effective from April 1, 2026, with Madhu Sundar transitioning from his current role as Head Global Manufacturing FTO Oral Solid Dosages (OSD) & Operational Excellence (OE). As part of this elevation, he will also serve as Senior Management Personnel and be inducted as a Member of Management Council.

Professional Background

Madhu Sundar brings extensive experience to his new role, currently serving as the Head of Formulation Manufacturing of 7 OSD units within the Global Manufacturing Organization. He also leads the Operations Excellence program of the Global Manufacturing Organization. His educational credentials include a post-graduate degree in Chemistry and an M. Tech degree in advanced analytical chemistry from IIT Delhi.

With 28 years of industrial experience, Madhu Sundar has handled diverse assignments across manufacturing, quality management, regulatory affairs, and supply chain operations. He joined Dr. Reddy's Laboratories in October 2017 as a site head and has progressively assumed positions of increasing responsibility within the organization. He has been serving in his current role since December 2023.

Additional Senior Management Changes

The company has also announced role changes for several other senior management personnel, all effective from April 1, 2026:

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was communicated to multiple stock exchanges including the National Stock Exchange of India Ltd., BSE Limited, New York Stock Exchange Inc., and NSE IFSC Ltd. on March 10, 2026.

These leadership changes reflect the company's strategic focus on strengthening its management structure across key operational areas including quality, manufacturing, and product development functions.

Dr. Reddy's Laboratories has received regulatory clearance from the United States Food & Drug Administration (USFDA) for its formulations manufacturing facility in Srikakulam, Andhra Pradesh. The pharmaceutical company announced that it has received the Establishment Inspection Report (EIR) with a favorable outcome.

USFDA Inspection Outcome

The USFDA has classified the inspection outcome as 'Voluntary Action Indicated (VAI)' and officially closed the inspection. The company received confirmation that the USFDA conducted a GMP and Pre-Approval Inspection at the Srikakulam facility, with the regulatory authority determining that the inspection process has been completed.

Regulatory Significance

The VAI classification indicates that the USFDA found objectionable conditions during the inspection but determined that the issues do not meet the threshold for regulatory or administrative action. This classification allows the facility to continue operations while addressing any identified concerns voluntarily. The official closure of the inspection provides regulatory certainty for the company's manufacturing operations at the Srikakulam facility.

Manufacturing Operations Impact

With the USFDA inspection now officially closed and classified as VAI, Dr. Reddy's Laboratories can continue its formulations manufacturing activities at the Srikakulam facility. The completion of this regulatory process ensures compliance with USFDA standards and maintains the facility's operational status for serving both domestic and international markets.